
Castle Biosciences Raises 2026 Outlook After Revenue Growth
With second-quarter revenue climbing to $103.5 million, Castle Biosciences is lifting its full-year financial forecast to a range of $365 million to $375 million. The diagnostics company credits the upward revision to robust demand for its core testing products, specifically in oncology and gastroenterology.




























